{"entity":{"type":"insider","cik":"0001274408","url":"/insider/0001274408","json_url":"/insider/0001274408.json","name":"ARCH VENTURE PARTNERS V LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":7,"n_filings":5,"first":"2006-10-19","last":"2011-07-25","span_basis":"filed_date"},"name_variants":[{"name":"ARCH VENTURE PARTNERS V LLC","source":"filing","n_filings":5,"first_seen":"2006-10-19","last_seen":"2011-07-25"}],"transactions":[{"id":8857281,"accession":"0001012975-11-000224","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-11-000224","line_url":"/filing/0001012975-11-000224#line-1","is_derivative":false,"issuer_cik":"0001054117","issuer_name":"NeurogesX Inc","issuer_ticker":"NGSX","issuer_name_source":null,"issuer_url":"/issuer/0001054117","owner_cik":null,"owner_name":"ARCH VENTURE PARTNERS V LP; CRANDELL KEITH; ARCH VENTURE FUND V LP; ARCH VENTURE PARTNERS V LLC; BYBEE CLINTON; NELSEN ROBERT; LAZARUS STEVEN","owner_display_name":"ARCH VENTURE PARTNERS V LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1744186.0,"shares_display":"1,744,186","price_per_share":1.65,"price_display":"1.65","price_state":"stated","total_value":2877906.9,"total_display":"2,877,906.90","total_whole":"2,877,907","shares_owned_after":4187777.0,"shares_owned_after_display":"4,187,777","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-07-21","filed_date":"2011-07-25","scope":"insider"},{"id":7424514,"accession":"0001012975-10-000380","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001012975-10-000380","line_url":"/filing/0001012975-10-000380#line-3","is_derivative":false,"issuer_cik":"0001054117","issuer_name":"Trubion Pharmaceuticals, Inc","issuer_ticker":"TRBN","issuer_name_source":null,"issuer_url":"/issuer/0001054117","owner_cik":null,"owner_name":"LAZARUS STEVEN; ARCH V ENTREPRENEURS FUND LP; HEALTHCARE FOCUS FUND LP; ARCH VENTURE PARTNERS V LP; CRANDELL KEITH; ARCH VENTURE FUND V LP; ARCH VENTURE PARTNERS V LLC; NELSEN ROBERT; BYBEE CLINTON","owner_display_name":"LAZARUS STEVEN","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2209741.0,"shares_display":"2,209,741","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-10-28","filed_date":"2010-11-01","scope":"insider"},{"id":7424512,"accession":"0001012975-10-000380","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001012975-10-000380","line_url":"/filing/0001012975-10-000380#line-2","is_derivative":false,"issuer_cik":"0001054117","issuer_name":"Trubion Pharmaceuticals, Inc","issuer_ticker":"TRBN","issuer_name_source":null,"issuer_url":"/issuer/0001054117","owner_cik":null,"owner_name":"LAZARUS STEVEN; ARCH V ENTREPRENEURS FUND LP; HEALTHCARE FOCUS FUND LP; ARCH VENTURE PARTNERS V LP; CRANDELL KEITH; ARCH VENTURE FUND V LP; ARCH VENTURE PARTNERS V LLC; NELSEN ROBERT; BYBEE CLINTON","owner_display_name":"LAZARUS STEVEN","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":132802.0,"shares_display":"132,802","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-10-28","filed_date":"2010-11-01","scope":"insider"},{"id":7424507,"accession":"0001012975-10-000380","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-10-000380","line_url":"/filing/0001012975-10-000380#line-1","is_derivative":false,"issuer_cik":"0001054117","issuer_name":"Trubion Pharmaceuticals, Inc","issuer_ticker":"TRBN","issuer_name_source":null,"issuer_url":"/issuer/0001054117","owner_cik":null,"owner_name":"LAZARUS STEVEN; ARCH V ENTREPRENEURS FUND LP; HEALTHCARE FOCUS FUND LP; ARCH VENTURE PARTNERS V LP; CRANDELL KEITH; ARCH VENTURE FUND V LP; ARCH VENTURE PARTNERS V LLC; NELSEN ROBERT; BYBEE CLINTON","owner_display_name":"LAZARUS STEVEN","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14503.0,"shares_display":"14,503","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-10-28","filed_date":"2010-11-01","scope":"insider"},{"id":8108538,"accession":"0001012975-07-000504","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-07-000504","line_url":"/filing/0001012975-07-000504#line-1","is_derivative":false,"issuer_cik":"0001054117","issuer_name":"NeurogesX Inc","issuer_ticker":"NGSX","issuer_name_source":null,"issuer_url":"/issuer/0001054117","owner_cik":null,"owner_name":"ARCH VENTURE PARTNERS V LLC; ARCH VENTURE FUND V LP; ARCH VENTURE PARTNERS V LP; CRANDELL KEITH; LAZARUS STEVEN; BYBEE CLINTON; NELSEN ROBERT","owner_display_name":"ARCH VENTURE PARTNERS V LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":382170.0,"shares_display":"382,170","price_per_share":6.18,"price_display":"6.18","price_state":"stated","total_value":2361810.6,"total_display":"2,361,810.60","total_whole":"2,361,811","shares_owned_after":2443591.0,"shares_owned_after_display":"2,443,591","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-12-24","filed_date":"2007-12-27","scope":"insider"},{"id":7689387,"accession":"0001012975-07-000251","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-07-000251","line_url":"/filing/0001012975-07-000251#line-1","is_derivative":false,"issuer_cik":"0001054117","issuer_name":"NeurogesX Inc","issuer_ticker":"NGSX","issuer_name_source":null,"issuer_url":"/issuer/0001054117","owner_cik":null,"owner_name":"ARCH VENTURE PARTNERS V LP; CRANDELL KEITH; BYBEE CLINTON; ARCH VENTURE FUND V LP; ARCH VENTURE PARTNERS V LLC; LAZARUS STEVEN","owner_display_name":"ARCH VENTURE PARTNERS V LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":227000.0,"shares_display":"227,000","price_per_share":11.0,"price_display":"11.00","price_state":"stated","total_value":2497000.0,"total_display":"2,497,000.00","total_whole":"2,497,000","shares_owned_after":227000.0,"shares_owned_after_display":"227,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-05-02","filed_date":"2007-05-04","scope":"insider"},{"id":2613976,"accession":"0001012975-06-000410","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-06-000410","line_url":"/filing/0001012975-06-000410#line-1","is_derivative":false,"issuer_cik":"0001054117","issuer_name":"Trubion Pharmaceuticals, Inc","issuer_ticker":"TRBN","issuer_name_source":null,"issuer_url":"/issuer/0001054117","owner_cik":null,"owner_name":"BYBEE CLINTON; ARCH VENTURE FUND V LP; ARCH VENTURE PARTNERS V LLC; ARCH VENTURE PARTNERS V LP; CRANDELL KEITH; LAZARUS STEVEN; NELSEN ROBERT","owner_display_name":"BYBEE CLINTON","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":44640.0,"shares_display":"44,640","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":580320.0,"total_display":"580,320.00","total_whole":"580,320","shares_owned_after":68402.0,"shares_owned_after_display":"68,402","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-10-17","filed_date":"2006-10-19","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001385830","name":"NeurogesX Inc","url":"/issuer/0001385830","role":"Ten percent owner","n_filings":3,"first_seen":"2007-05-04","last_seen":"2011-07-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001298521","name":"Trubion Pharmaceuticals, Inc","url":"/issuer/0001298521","role":"Ten percent owner","n_filings":2,"first_seen":"2006-10-19","last_seen":"2010-11-01"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001274408","retrieved_at":"2026-08-24T03:16:34+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}